Merck - 54 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of July 02, 2024 is 127.72.
  • The all-time high Merck stock closing price was 132.96 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 5.4% above the current share price.
  • The Merck 52-week low stock price is 99.14, which is 22.4% below the current share price.
  • The average Merck stock price for the last 52 weeks is 115.98.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 125.1100 111.8456 132.9600 111.8456 127.7200 18.61%
2023 105.2169 106.7976 114.5311 98.2320 107.6776 1.00%
2022 84.8980 71.5838 107.7394 68.4549 106.6151 49.38%
2021 70.6750 72.7599 83.5319 64.8602 71.3696 -2.92%
2020 71.3988 80.1798 80.1798 58.3035 73.5148 -7.21%
2019 70.5609 64.1082 79.9185 61.8438 79.2303 22.26%
2018 53.5522 46.2486 66.8081 44.1756 64.8036 40.00%
2017 50.2955 48.0039 53.9632 44.1265 46.2897 -1.47%
2016 45.1113 40.5732 51.4513 37.5657 46.9824 15.05%
2015 42.9274 42.7804 47.1490 37.1070 40.8360 -3.87%
2014 42.0824 35.9184 45.9404 35.9184 42.4812 16.95%
2013 33.0080 28.9267 36.3248 28.5838 36.3248 26.80%
2012 28.2539 25.7258 33.2337 25.0609 28.6468 13.13%
2011 22.3389 23.1177 25.4572 19.5516 25.3228 9.54%
2010 22.5718 22.7635 25.2361 19.7730 23.1177 2.86%
2009 17.7444 18.0842 23.3724 12.4456 22.4744 26.73%
2008 21.0395 32.0327 33.8083 13.5494 17.7342 -45.34%
2007 27.8678 23.8493 33.9311 23.2642 32.4459 37.36%
2006 20.3465 17.0479 24.8247 17.0479 23.6218 42.66%
2005 15.5216 15.4802 17.5056 13.2844 16.5586 4.04%
2004 20.3202 22.4388 23.4293 12.7013 15.9159 -27.76%
2003 24.0996 25.5744 28.1350 19.1999 22.0334 -11.35%
2002 23.3894 25.5814 27.7087 16.9165 24.8544 -1.26%
2001 30.0462 38.9364 38.9364 24.4727 25.1704 -35.79%
2000 30.6119 27.8298 39.6691 22.3037 39.2002 41.78%
1999 29.8821 30.3485 35.1205 24.8773 27.6488 -7.47%
1998 25.8854 21.4643 32.1516 20.5267 29.8825 41.32%
1997 18.6607 15.6439 21.4044 15.6439 21.1451 35.61%
1996 13.1735 12.3184 16.4169 10.9827 15.5930 23.92%
1995 9.3712 7.1731 12.8226 6.8218 12.5830 76.57%
1994 6.1090 6.3637 7.3600 5.1683 7.1264 14.82%
1993 6.2336 7.6891 7.6891 5.1043 6.2067 -18.35%
1992 8.4149 9.5296 9.6722 7.1679 7.6015 -20.29%
1991 6.8028 5.0276 9.5364 4.6203 9.5364 88.88%
1990 4.3801 4.3065 5.0489 3.7001 5.0489 18.95%
1989 3.8125 3.0610 4.3565 3.0610 4.2446 37.47%
1988 2.8873 2.8577 3.1603 2.5296 3.0877 12.05%
1987 2.9227 2.1906 3.7814 2.1906 2.7556 27.95%
1986 1.6622 1.1996 2.2514 1.1768 2.1536 80.84%
1985 0.9545 0.8096 1.1909 0.7857 1.1909 45.75%
1984 0.7704 0.7857 0.8432 0.6933 0.8171 4.00%
1983 0.7906 0.7302 0.9062 0.7128 0.7857 6.81%
1982 0.6683 0.7432 0.7628 0.5585 0.7356 -0.15%
1981 0.7556 0.7476 0.8900 0.6650 0.7367 0.00%
1980 0.6324 0.6150 0.7367 0.5107 0.7367 17.29%
1979 0.5869 0.5901 0.6421 0.5443 0.6281 6.86%
1978 0.5006 0.4661 0.6009 0.4184 0.5878 21.82%
1977 0.4882 0.5824 0.5824 0.4379 0.4825 -18.52%
1976 0.6217 0.6053 0.6987 0.5476 0.5922 -1.63%
1975 0.6474 0.5846 0.7432 0.5107 0.6020 4.33%
1974 0.6248 0.6987 0.7443 0.4259 0.5770 -17.79%
1973 0.7765 0.7867 0.8736 0.6759 0.7019 -9.40%
1972 0.6639 0.5444 0.7780 0.5444 0.7747 43.73%
1971 0.4607 0.4129 0.5683 0.4129 0.5390 25.26%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $270.018B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12